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Abstract
Background: High prevalence rates of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) have been
reported in Aboriginal people in remote and regional areas of Australia for well over two decades, and repeat
positivity rates are high. To interrupt disease transmission and reduce the risk of complications, early diagnosis and
treatment is important. However in many remote and regional areas there are long delays between testing for
these curable sexually transmissible infections and providing treatment, due to both physical distance from
laboratories and difficulties when recalling patients for subsequent management once results are available. Point-of-
care (POC) tests have the potential to provide more timely diagnosis, to increase treatment and contact tracing,
and in turn reduce CT and NG infection rates.
Methods/design: TTANGO (Test, Treat, ANd GO) is a cross-over cluster randomised controlled trial in 12 regional or
remote Australian health services, which predominantly provide clinical services to Aboriginal people. The overall
aim of TTANGO is to measure the clinical effectiveness, cost-effectiveness and cultural and operational acceptability
of molecular POC testing for CT and NG infection. The primary outcome is repeat positivity at three months after
treatment of an initial CT or NG infection.
Participating health services will undertake the clinical management of CT and NG under two different modalities
for one year each. In the first year, six health services will be randomly assigned to manage these infections under
current diagnostic guidelines. The other six will supplement current diagnostic guidelines with POC testing,
whereby diagnosis is made and subsequent treatment for those with positive POC tests is offered at the initial
consultation. In the second year, the health services will cross over to the opposite management modality.
TTANGO will be conducted over four years; 1.5 years of trial initiation and community consultation, 2 years of trial
conditions and evaluation, and 6 months of data analysis and feedback.
Discussion: TTANGO is the first cluster randomised trial of POC testing for CT and NG internationally. The results of
this trial will provide crucial information to guide sexual health clinical practice in remote Aboriginal communities
and other high prevalence settings.
Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12613000808741
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Background
Chlamydia trachomatis (CT) and Neisseria gonorrhoea
(NG) are sexually transmissible infections (STIs) that are
fully curable with single dose treatment but are often
asymptomatic for long periods of time [1]. Both infec-
tions can lead to serious complications [1] including pel-
vic inflammatory disease (PID) [2], ectopic pregnancy
and tubal factor infertility [3,4], and a range of adverse
pregnancy and neonatal outcomes [5,6]. The risk of PID
increases by 4–6 fold in women with repeated CT infec-
tions [7].
Along with several other STIs, CT and NG have been
reported at highly elevated rates in Aboriginal and
Torres Strait Islander peoples (hereafter referred to as
‘Aboriginal’) in Australia. According to the most recent
national data, CT and NG were 3.6 and 30.6 times [8]
more likely to be diagnosed in Aboriginal people, re-
spectively, compared to the non-Indigenous population.
As in many areas of health, the disadvantage experi-
enced by Aboriginal people is amplified in regional
and remote communities, where more Aboriginal
Australian’s reside. Aboriginal people comprise approxi-
mately 2.5% of the total Australian population, yet 25%
live in remote or very remote areas compared with < 2%
of non-Indigenous people [9]. In 2011, CT and NG were
diagnosed 8.3 and 61 times more often among Aborigi-
nal people in remote areas, respectively, compared to
non-Indigenous people in remote areas, and diagnoses
rates were highest in young people aged 16–19 years [8].
Marked differences in rates of diagnosis among Aborigi-
nal people are also evident according to area of resi-
dence; in 2011 CT and NG were diagnoses were 2.5 and
11 times higher in remote areas, respectively, compared
to Aboriginal people in major cities [8]. Although the
complications of CT and NG are not systematically
monitored in Australia, clinical reports from remote
Aboriginal communities in Central and Northern
Australia indicate that PID and infertility occur at rates
far higher than in other parts of Australia [10-12].
In regional and remote areas, primary health services
play an important role in the prevention, testing, treat-
ment and management of CT and NG. These health ser-
vices are either State or Territory government funded or
Federal government funded Aboriginal Community
Controlled Health Services (ACCHS) and are the pri-
mary health care provider for Aboriginal people. There
are an estimated 150 ACCHS located across Australia.
Current clinical practice in most remote Aboriginal
communities [13-15] follows guidelines which provide
for immediate treatment if NG or CT are suspected on
the basis of specified symptoms or risk [16]. Although
symptom-driven diagnosis has the advantage of provid-
ing a rapid pathway to treatment, it has poor sensitivity
and specificity for detecting infection, particularly in
women [17,18]. Used as a diagnostic strategy on its own
it therefore leaves many infections untreated, and results
in unnecessary treatment in others.
As CT infections are mainly asymptomatic, and NG
infections are mainly asymptomatic in women and in
about 50% of men [19-21], treatment and contact tracing
is usually initiated once a specimen has been tested and
found positive by the laboratory. Treatment for these in-
fections is almost inevitably delayed due to a range of
factors including the time taken to transport the speci-
men from remote health services to laboratories [22],
and delays in recalling patients when a positive diagnosis
occurs. Some health services are more than 1000 kilo-
meters away from the laboratory and pathology is sent
on a weekly basis by small plane. A recent review of STI
programs in remote Aboriginal communities showed
that in a 12 month period only 75-89% of people diag-
nosed with an STI were treated, and the average time
from diagnosis to treatment in asymptomatic people was
21 days [23] , far longer than the 2–3 day interval expe-
rienced in most urban settings [24].
In order to interrupt disease transmission, it is essen-
tial to diagnose and provide treatment as early as pos-
sible to reduce the average duration of infection among
those with CT and NG [25]. Without treatment, infec-
tion with CT and NG can persist for on average
12 months and 6 months, respectively [26-28]. Timely
diagnosis also reduces the risk of sequelae. A number of
studies have found that within just a few weeks between
testing and treatment, 2-3% of patients with CT infec-
tion have already developed PID [29,30]. Timely diagno-
sis also enables potentially infected sex partners to be
contacted and treated (contact tracing), and in turn re-
ducing the risk of re-infection in the index case which
often occurs due to subsequent sex with an untreated
existing partner [31]. Repeat chlamydial infections fol-
lowing treatment are also common. In a prospective co-
hort of young women in urban Australia, the repeat CT
positivity rate was found to be 22.3% by 12 months [32].
Data based on routine re-testing remote Australian Abo-
riginal communities found the CT and NG repeat posi-
tivity rates was 50% within 12 months [33].
The use of point-of-care (POC) testing in the Australian
Indigenous health sector is well established for chronic dis-
eases (diabetes and renal diseases) through the national
‘QAAMS’ (Quality Assurance for Aboriginal and Torres
Strait Islander Medical Services) Program, which currently
operates in over 170 Aboriginal medical services nationally
[34,35]. POC tests for CT and NG would be the first use of
infectious disease POC tests in this sector and could enable
clinical services to offer treatment and begin the process of
contact tracing at the initial consultation. However to date,
use of CT and NG POC tests has been limited as only lat-
eral flow devices have been commercially available with
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poor sensitivity and specificity [36,37]. Recently, molecular
CT and NG POC tests have been developed, which have
very high sensitivity and specificity of >95%, providing an
opportunity to utilize these tests to control infections rates
in high prevalence settings [38]. Mathematical modeling by
Hui et al. [39] has shown that CT/NG POC tests with 95%
sensitivity could reduce the prevalence of CT in remote
Aboriginal communities from 11.9% to 8.9% and NG from
7.1% to 5.7% and if the annual STI screening coverage is in-
creased from 44% (estimated current rates) to 60% the
prevalence of the infections could drop further to 3.1% and
1.8% for CT and NG, respectively.
The overall aim of the TTANGO trial is to measure
the clinical effectiveness, cost-effectiveness and cultural
and operational acceptability of POC testing for CT and
NG infections in remote Aboriginal communities. The
primary objective is:
1. To determine whether the addition of POC testing
to standard diagnostic procedures significantly
decreases rates of repeat positive infections at three
months among people with CT or NG infection in
remote communities.
The secondary objectives are to determine:
1. Whether the addition of POC testing to standard
diagnostic procedures significantly increases the
proportion of CT and NG infections treated within
seven days of specimen collection;
2. The cultural acceptability of POC tests to patients.
3. The operational acceptability to health service staff
in remote community settings.
4. The cost effectiveness of the addition of POC testing
to standard diagnostic procedures in remote primary
health care services.
5. The diagnostic performance characteristics
(sensitivity, specificity and positive and negative
predictive value) of the POC test in a field setting
compared to conventional laboratory testing.
6. A best practice model for quality management of
STI/POC testing in remote health services.
Methods
Study design
TTANGO is a crossover cluster randomised controlled trial
set in 12 health services in regional or remote areas of
Queensland, West Australia and South Australia (Figure 1:
Study overview). Participating health services will undertake
the clinical management of CT and NG under two different
parallel modalities for one year each, in a randomly
assigned order. In the first year, six of the health services
will be randomly assigned to manage these infections under
current diagnostic guidelines (“standard practice” phase or
“control” phase). The other six will supplement current
diagnostic guidelines with POC testing (“POC” phase), such
that diagnosis is made and subsequent treatment for those
with positive POC tests is offered at the time of initial con-
sultation. In the second year, the health services will cross
over to the opposite management modality. The study will
require four years to complete, including 1.5 years prepar-
ation and community consultation, 2 years for the interven-
tion and evaluation, and 6 months for analysis and
reporting. The fundamental premise of the trial is that
more timely treatment for STIs (both index case and part-
ners), will result in a substantial reduction in the percentage
of people with repeat positive CT and NG infections.
A randomised trial is required because it will provide
the most compelling evidence to guide future use of a
novel technology which is currently not routinely used
for STI management. The cross-over design allows each
health service to act as its own control, thereby eliminat-
ing the effect of between-health service variation in the
study endpoints. Furthermore, health services are more
inclined to participate in a trial of an innovative ap-
proach to service delivery if they are guaranteed to re-
ceive the intervention during the course of the trial.
Individual patient randomisation would not be feasible
as the POC tests would then be used for some patients
but not others within the same health service, potentially
causing disruption and confusion for health service staff
and patients.
CT and NG are the focus of the trial, because they
occur at very high rates in remote Aboriginal communi-
ties and are easily detected and curable with single dose
treatment, making them good candidates for strategies
which aim to improve detection and treatment of infec-
tions with antibiotics. Although syphilis is also curable
and has been endemic in some remote communities,
rates have decreased considerably over the past decade
and is now much rarer than the other STIs [8]; also at
the time of the trial design syphilis point-of-care tests
were unable to differentiate recent from past syphilis in-
fection [40]. Despite its focus on CT and NG, TTANGO
encourages best practice for the detection and treatment
of all STIs.
Ethics and informed consent
The TTANGO study protocol has been approved by five
ethics committees from participating jurisdictions: the
Western Australian Aboriginal Health Information Eth-
ics Committee, the Western Australian Country Health
Service Board Research Ethics Committee, the Cairns
and Hinterland Health Service Human Research Ethics
Committee, the Townsville Health Service District Hu-
man Research Ethics Committee and the Aboriginal
Health Research Ethics Committee of South Australia.
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Participating health services sign a Site Participation
Agreement prior to commencement of their involvement
in TTANGO. This agreement outlines trial details, re-
sponsibilities of the research team and participating ser-
vices, principles of confidentiality and data ownership,
and defines processes for reporting of findings and pub-
lic release of study results.
Community engagement and collaboration
Engagement with stakeholders including Government,
state-based Aboriginal Community Controlled Health
Organisations (which represent ACCHSs in each state),
and laboratories will be a key principle of the TTANGO
trial. Effective community engagement will ensure that
an appropriate framework is developed to guide project
implementation, and that transparency is maintained at
all levels.
Identification of communities and health services and
eligibility criteria
In the first instance, potentially eligible health services will
be identified in consultation with Government and Aborigi-
nal Community Controlled Health Organisations. Identified
health services will then be approached and invited to par-
ticipate in TTANGO if they meet the following inclusion
criteria: located in communities classified as regional, re-
mote or very remote by the Australian Bureau of Statistics
[41]; annually offer CT and NG testing to a minimum of
150 people aged 16–29 years (see sample size section), with
a CT and NG positivity of at least 10% in 16–29 year olds;
agree to be randomly assigned in one year out of two to the
Figure 1 Trial overview.
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POC phase; have an electronic patient management system;
and have the staff and resource capacity to fulfil protocol
requirements.
Randomisation
Health services within the four geographic regions will
be randomised to intervention (“POC” phase) or control
arm (“standard practice” phase) strategies for year one in
a 1:1 ratio, and will cross over to the opposite arm in
year two. Randomisation within geographic regions is
mainly for pragmatic reasons so that the TTANGO co-
ordinators are able to manage workload appropriately,
and avoid the possibility of all services in one region be-
ing randomised to the same study arm. The randomisa-
tion scheme will be developed by the TTANGO
statistician using SAS statistical software (Version 9.3)
and will be communicated to participating health ser-
vices once participation agreements have been signed.
During the POC Phase health services will continue
routine STI testing and management practices (syn-
dromic management, and sending off specimens to la-
boratories for routine NAAT tests) but will supplement
their activity with CT and NG POC testing, so treatment
and management of positive CT and NG POC tests oc-
curs at the time of initial consultation. The POC test se-
lected for the trial is the GeneXpert CT/NG® (Cepheid)
which is a new test based on nucleic acid amplification
technology, with dual detection of CT and NG in under
90 minutes. The GeneXpert CT/NG POC test had been
demonstrated in laboratory and field evaluations in
Australia [42,43] and the US [44] to have similar sensi-
tivity and specificity to routine laboratory based NAAT
tests, and was easy to use. The test has 5 targets, includ-
ing a specimen processing control, specimen adequacy
control, one CT target and two targets for NG. Two sep-
arate targets for NG allows for more specific detection
and confirmation of NG [45]. The GeneXpert CT/NG
test was approved by the Therapeutic Goods Adminis-
tration for diagnostic purposes in Australia in March
2013, and obtained Conformité Européenne (CE) mark-
ing and US Food and Drugs Administration (FDA) clear-
ance in 2012.
During the Standard Practice phase health services
will maintain routine STI testing and management prac-
tices involving syndromic management, and sending off
specimens to laboratories for routine NAAT tests, with
treatment and management of asymptomatic infections
based on the results that are received from the labora-
tory. The NAAT tests commonly used at the laboratories
are the Roche Cobas and the Gen Probe Aptima.
Health services in both trial phases will receive clinical
performance incentives and will participate in STI quality
improvement (see further details below). Health services
operating in the POC Phase will receive POC training
and ongoing support and will participate in laboratory
quality management procedures (see below).
STI quality improvement
In both trial phases, de-identified clinical and laboratory
data will be used to generate regular site specific reports
on STI screening and management. Reports will show
the percentage of health centre attendees patients tested
for STIs, the percentage testing positive, time to treat-
ment, the percentage re-tested 3 months after treatment,
and the percentage with a repeat positive result at re-
test. The reports will be discussed at initial and subse-
quent visits, and are intended to assist services to reflect
on current practice and develop strategies to achieve
best practice in STI service delivery [16,46,47]. Accord-
ingly, health services will be supported to increase and
appropriately target opportunistic STI testing, provide
treatment promptly where indicated, and follow
recommended guidelines for re-testing and contact tra-
cing. Where necessary, TTANGO coordinators will re-
spond to identified training needs to strengthen sexual
health service delivery.
Clinical performance incentives
In both trial phases, health services will receive incentive
payments at six monthly intervals. Payments will be
slightly higher in the POC phase, in recognition of the
additional time spent fulfilling trial data collection re-
quirements. Over the course of the trial (POC phase and
Standard Practice phase), health services will be eligible
to receive a maximum of $5000. In the POC phase, pay-
ments will be on the basis of $20 per POC test, up to a
maximum of 150 tests, and $30 per re-test in clients
who test positive. In the standard practice phase, pay-
ments will be on the basis of $10 per test, up to a max-
imum of 150 tests, and $30 per re-test in clients who
test positive. Trial coordinators will provide support in
both phases of the trial to strengthen testing and re-
testing practices.
POC training and support
In the POC phase, health service personnel will be
trained onsite in use of the GeneXpert machine,
complete a competency assessment, and will be provided
with all materials necessary to perform POC testing
throughout the POC phase. ‘Real-time’ monitoring and
support will be provided remotely by TTANGO coordi-
nators, through the use of ‘LogMeIn’ software. Trial co-
ordinators will also provide support at their 6-monthtly
visits and by phone/email.
Quality management for POC processes
The trial will incorporate Quality Management proce-
dures to ensure that QM is conducted and that data are
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generated, documented and reported in compliance with
good clinical laboratory practice. Standard operating
procedures (SOPs) for POCT have been developed and
are reinforced through POCT training and competency
assessment processes, and compliance with SOPs is
monitored during site visits. Any specimens generating
discordant results (between laboratory reference test and
the GeneXpert) will be stored at the local laboratory,
and at the end of the trial transferred to a research la-
boratory for re-testing with the COBAS 4800 test.
Whilst the GeneXpert machine has a range of sophisti-
cated built-in quality test processes, health services will
be required to test a known positive “in house” quality
control sample (consisting of non-infectious DNA of
both CT and NG and prepared to simulate an infection
of average bacterial load) each month and four blinded
external quality assurance samples twice during the trial.
The quality assurance procedures were developed by the
National Serology Reference Laboratory for this trial and
involve sending out swabs with freeze-dried organism
(CT, CT and NG, NG and negative) [48].
Outcome measures
The primary outcome is repeat positivity at three
months after treatment among people with CT or NG
infection.
The secondary outcomes are:
1. Proportion of infections treated within seven days of
specimen collection.
2. Cultural acceptability of POC tests to patients.
3. Operational acceptability of POC tests to health
service staff in remote community settings.
4. The cost effectiveness of the addition of POC testing
to standard diagnostic procedures.
5. The sensitivity, specificity, negative and positive
predictive value of the POC test in a field setting
compared to the reference laboratory test.
6. A best practice model for quality management of
STI/POC testing in remote health services.
Data collection methods and variables
The trial will utilise a number of methods to collect infor-
mation to calculate the trial outcomes above and these are
described in further details in Table 1. Confidentiality will
be maintained at all levels of data collection, transfer and
analysis by de-identifying participating health services, staff,
patients and other key stakeholders.
Sample size
Power calculations were performed using the methods of
Julious et al. [49], for paired binary comparisons and Hayes
et al. [50] for community randomised trials. We assumed
that the prevalence of CT and/or NG will be 15% at
recruitment to the trial in each year, that 30% of patients
will have a positive re-test within three months (in the
standard practice phase), and that at least 150 patients aged
16–29 years will be tested at each health service in both
POC and standard practice years. Table 2 shows the total
number of health services needed to detect a reduction in
CT and NG repeat positivity rate from 30% in control
health services to 15% in intervention health services with
80% and 90% power, differing community coefficients of
variation (0.25, 0.30) and equal numbers of health services
in each arm. At least ten services will provide data in both
the intervention and control arms. This will ensure 88%
power to detect a decrease in CT and NG repeat positivity
rate from 30% to 15%, and 78% power to detect a reduction
from 20% to 10%. Conservatively, 12 services will be in-
cluded in the trial.
Statistical analysis
We will compare results between the two years (with
and without POC testing) from within the 150 patients
aged 16–29 tested each year in participating health ser-
vices. Characteristics of participating health services will
be summarized at baseline and across trial arms (stand-
ard practice or POC phase). The primary endpoint of
the study will be the health service specific difference
between the two years in repeat positivity rates at three
months. The secondary endpoint will be the health ser-
vice specific difference between the two years in the pro-
portion of true CT and NG infections that were treated
within seven days of presentation. For both the primary
and secondary endpoints, the average difference between
the two years (with and without POC tests) will be cal-
culated across participating health services. Other sec-
ondary outcomes will be measured as follows:
Cultural acceptability of POC tests to patients: will be
assessed by a descriptive analysis of questionnaire feed-
back received from patients.
Operational acceptability of POC tests to health service
staff in remote community settings: will be assessed by
calculating the proportion of staff who indicated that
they agreed or strongly agreed on the Likert scale with
the acceptability questions in the staff questionnaire.
The cost effectiveness of the addition of POC testing to
standard diagnostic procedures: The treatment interval,
repeat positivity rate and contact tracing data collected
in this trial will enable us to parameterise the models.
Our analyses will apply similar techniques to those used
by other studies in the context of POC tests [51,52], but
explicitly represent regional and remote Australian Abo-
riginal community settings. Our approach will extend
previous work by developing a more realistic model
based on simulated sexual networks rather than popula-
tion averages. The mathematical approach will use an
individual-based model to enable us to accurately
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simulate and track repeat positivity rates, which is not
possible with previous models. The epidemiological
transmission models will project the estimated preva-
lence, incidence and repeat positivity rates expected
from implementing POC tests in communities.
These model outputs will become inputs in a health
economics analysis. The cost of using POC tests in re-
gional and remote health services including the in-
creased clinician and patient waiting time for POC tests
and the patient costs incurred in a return visit to the
health service for medication after a positive test result
will be directly measured in the trial. These data will be
used to estimate the additional cost of implementing
POC tests in combination with NAAT testing, compared
to standard diagnostic procedures. Costs related to re-
search will be excluded.
The total costs associated with the widespread imple-
mentation of POC tests, including estimated logistical,
clinical and administrative costs, will be compared with
the long-term health and financial savings associated
with their use (including the prevention of new infec-
tions, co-morbidities, and saving in reduced quality of
life as well as costs of treatment saved due to decreased
infections). As is standard with health economic ana-
lyses, discounting will be applied at levels of 0%, 3% and
5%. The health economic analyses will be carried out
from the perspectives of the provider and the client. The
integrated epidemiological and economic modelling will
examine issues of allocation, efficiency, and cost-
effectiveness.
The sensitivity, specificity, negative and positive pre-
dictive value of the POC test in a field setting compared
to the reference laboratory test: POC test performance
will be assessed by comparing the results of the POC
tests performed during the POC phase with the refer-
ence test (NAAT).
Table 2 Sample size estimates based on reduction in
repeat positivity rate from 30% to 15%
Coefficient of variation Number of services
80% power 90% power
25% 8 10
30% 10 14
Table 1 Tools, methods and description of information collected in the trial
Tool Method and frequency Description of data collected
Site assessment
tool
• Completed by TTANGO Coordinators at baseline,
and updated 6 monthly in all health services.
Broad description of:
(i) Clinical services and staffing
(ii) STI testing practices
(iii) Patient information system




• Collated from one or more of the following
sources:
(i) Patient consultation data and associated demographics
(i) Health service patient information management
systems
(ii) STI testing (point of care and laboratory), retesting and treatment
outcomes
(ii) Laboratory data




• Services record results of EQA and forward to
coordinators,
• External quality assurance and internal quality control test results
• twice during POC phase • Temperature range of consumables during transport
• Internal quality control testing, once per month • Multiple choice quiz and observed practice against competency standards
• Temperature monitoring of test consumables
during transport
• Knowledge and competency assessment of staff
following training in GeneXpert usage
Surveys
(quantitative)
• Staff acceptability survey at end of POC phase • Confidence using the test; satisfaction with training; trust in the results;
ease of use; experience of discordant results; and impact on health service
operations.• Client acceptability survey, with attending clients
in last month of POC phase
• Preference for testing modality (POC test vs conventional); convenience;




• Stakeholders (national) • Challenges and implications of introducing POC testing
• Stakeholders (national and international) • Quality management and training considerations
• Acceptability• Health service staff
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Discussion
Rates of CT and NG in remote Aboriginal communities
in Australia are unacceptably high, and TTANGO will
evaluate whether POC testing for these STIs can im-
prove the timeliness of treatment and in turn reduce re-
peat infection rates. To our knowledge, TTANGO will
be the first randomized trial of molecular POC tests for
CT/NG infection internationally.
It is anticipated that one of the main challenges for
TTANGO will be to sustain the involvement of health
service staff amidst the numerous competing demands
and health priorities, and also ensure POC operator
competency is maintained in the context of high staff
turnover. Regular communication and training with trial
sites from a dedicated TTANGO coordinator should
help to mitigate this risk. Another challenge will be if
the services randomised to the POC arm in the first year
prefer to keep the POC machines due to realized im-
provements in STI management. In the consultation
phase we emphasized to health services the importance
of the cross-over design to ensure long term policy
change and funding. Finally, repeat positivity rates are
calculated from those who re-tested and these need to
be similar in both POC and non-POC arms to minimize
biases – lower re-testing rates are often associated with
higher repeat positivity due to re-testing in those with
symptoms [53]. To mimimise any imbalance in re-
testing rates, a quality improvement program and incen-
tives associated with re-testing have been provided in
both arms.
This research is significant as study outcomes will
make an important contribution to the international un-
derstanding of STI control using POC tests. The re-
search may also lead to significant decreases in STI
prevalence and reinfection across multiple sites with
long term benefit for the sexual health and wellbeing of
young Aboriginal people. Finally, it has the potential to
influence public health policy and result in [54] uptake
of CT and NG POC tests into further remote clinical
services in Australia, and other settings.
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